• VX-765 and Caspase-1: Evidence in Pyroptosis Research

  2026-10-05

  VX-765 is a research compound described as a prodrug of the active caspase-1 inhibitor VRT-043198. This overview examines its conceptual relevance to IL-1β and IL-18 signaling, pyroptosis, and the 2026 study of cordycepin combined with photodynamic therapy in breast cancer cells. It distinguishes supplier claims from peer-reviewed evidence, evaluates what pharmacological caspase-1 inhibition can and cannot demonstrate, and outlines key translational limitations without providing experimental procedures.

• Dorsomorphin (Compound C) in Translational Research

  2026-10-05

  Dorsomorphin (Compound C) offers a useful chemical lens on AMPK, BMP/Smad, autophagy, differentiation, and metabolic stress. This thought-leadership analysis places its reported activity alongside Nrf2 findings from progressive rotavirus infection while defining the validation boundaries required for translational interpretation.

• Intravesical p21 mRNA-LNP Therapy: Evidence and Limits

  2026-10-04

  A source-grounded overview of a 2026 FASEB Journal study investigating intravesical delivery of chemically modified p21 mRNA in lipid nanoparticles for bladder cancer. The article examines the biological rationale, preclinical findings, evidence strength, translational relevance, and limitations, including the absence of human data and head-to-head comparisons with established intravesical therapies.

• MAPK10–KRT16 Signaling in NSCLC Metastasis

  2026-10-03

  A 2026 study reports that MAPK10 suppresses non-small cell lung cancer metastasis by phosphorylating KRT16 and promoting RNF213-dependent ubiquitination and proteasomal degradation. The findings connect kinase signaling with cytoskeletal protein turnover, while the clinical and animal evidence still requires broader validation before the pathway can be considered a therapeutic or prognostic standard.

• Ziprasidone HCl: GOT1 and Formulation Workflows

  2026-10-01

  Ziprasidone HCl supports two complementary research paths: receptor-centered neuroscience experiments and GOT1-focused cancer metabolism studies. Its poor aqueous solubility also makes it a practical model for testing hot-melt extrusion, permeability, and food-effect strategies.

• Lactate Workflows for Metabolic–Immune Research

  2026-10-01

  Use L-lactate as both a quantitative readout of glycolytic activity and a controlled perturbation for hypoxia, mitochondrial, tumor, and immune-cell studies. This workflow translates the NAT1–ENO1–lactate findings in colorectal cancer into practical sampling, dosing, normalization, and troubleshooting decisions.

• TCAIM Control of OGDH and Mitochondrial Metabolism

  2026-09-30

  A 2025 Molecular Cell study identifies TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds native OGDH and promotes its reduction through HSPA9 and LONP1. This mechanism links mitochondrial proteostasis to suppression of OGDH complex activity, altered carbohydrate catabolism, and broader metabolic regulation in cells and mice.

• Sulfachloropyridazine: From DHPS to Microbiomes

  2026-09-30

  Sulfachloropyridazine is a sulfonamide antibacterial agent whose value extends from DHPS biochemistry to infection-associated microbiome research. This article explains how to interpret enzyme, susceptibility, microbiome, and metabolomics data as connected but non-interchangeable evidence.

• Oltipraz Workflows for Nrf2 and MASLD Research

  2026-09-29

  Use Oltipraz as a defined Nrf2 pathway activator to connect phase II enzyme induction with autophagy, ferroptosis, and lipid-injury readouts in liver models. This workflow complements complex botanical interventions by providing a reproducible chemical comparator for mechanism-focused MASLD and chemoprevention research.

• KR-12: Copper-Aware Antimicrobial Assay Design

  2026-09-29

  KR-12 human antimicrobial peptide is more than a membrane-active LL-37 fragment: its Cu(II) coordination chemistry can influence how antimicrobial assays are designed and interpreted. This article connects peptide identity, membrane biology, metal binding, and endpoint selection for more rigorous KR-12 research.

• RNA Clean and Concentrator Kit Workflow

  2026-09-28

  Learn how to use the RNA Clean and Concentrator Kit to convert in vitro transcription products into cleaner, more reproducible inputs for mRNA formulation and functional assays. The workflow pairs membrane-based cleanup with practical QC and troubleshooting for p21 mRNA–LNP research inspired by a bladder cancer study.

• Hypoxia, Choroid Plexus Barrier, and Cognitive Impairment

  2026-09-28

  A mouse study links simulated high-altitude hypoxia to cognitive dysfunction through a proposed sequence involving oxidative stress, altered AMPK signaling, M1 macrophage polarization, and choroid plexus barrier disruption. The findings broaden attention beyond neuronal responses and suggest that barrier-associated immune changes are important targets for testing in hypoxia research.

• How Cholesterol Hinders LNP Intracellular Trafficking

  2026-09-27

  Luo and colleagues used a sensitive biotin–DNA tracking platform with high-throughput imaging to examine how lipid nanoparticle composition affects intracellular trafficking. Their findings link increased cholesterol to peripheral early-endosome accumulation, impaired progression along the endolysosomal pathway, and reduced nucleic-acid delivery—an effect partly alleviated by DSPC.

• OLIG2 mRNA Enables Rapid Oligodendrocyte Differentiation

  2026-09-26

  Xu and colleagues developed a non-integrating synthetic modified messenger RNA strategy to direct hiPSCs toward oligodendrocyte progenitor cells using an OLIG2 S147A construct. Their six-day induction approach produced NG2-positive cells at greater than 70% purity, which matured into functional oligodendrocytes in vitro and promoted remyelination in vivo, supporting further study of transient RNA-driven lineage programming.

• Fangchinoline Restores TFEB Lysosomal Defense Against H1N1

  2026-09-25

  The study identifies fangchinoline as a lysosome-accumulating compound that activates TFEB, restores lysosomal gene expression, and inhibits H1N1 infection, with time-resolved assays pointing to viral entry as a key affected stage. Its findings suggest a host-directed antiviral strategy, while also highlighting that lysosomal biogenesis, pH, and autophagic flux are related but distinct measures of cellular function.

8533 records 1/569 page Next 12345 下5页 Last page